The cagrilintide patent portfolio belongs to Novo Nordisk. Here's what the compound, formulation, and combination patents cover and when they expire.
The cagrilintide patent portfolio is owned by Novo Nordisk, which protects the drug with multiple overlapping patent families instead of a single filing. The earliest compound patents were filed in the early 2010s, so core protection runs into the early-to-mid 2030s in the United States and Europe. Formulation, dosing, and combination patents filed later can keep a cagrilintide product protected into the 2040s.
What the Cagrilintide Patent Portfolio Actually Covers
For anyone asking what is cagrilintide, the short answer is that it is an investigational amylin analog designed to be injected once a week. Amylin is a hormone released alongside insulin that slows stomach emptying and increases feelings of fullness, and cagrilintide mimics that signal with a fatty-acid chain that keeps it in circulation longer.
Novo Nordisk's cagrilintide filings generally fall into four layers:
- Compound patents — cover the cagrilintide molecule itself, including its amino acid sequence and the side chain that drives its long half-life.
- Formulation patents — cover stable liquid versions suitable for a multi-dose injection pen, including buffers, pH ranges, and preservatives.
- Dosing and method-of-use patents — cover specific weekly doses and titration steps studied in clinical trials.
- Combination patents — cover giving cagrilintide with a GLP-1 receptor agonist such as semaglutide, the pairing behind the CagriSema program.
This layered strategy is standard in peptide drug development. It also means a follow-on manufacturer would have to design around several patents at once rather than wait for one molecule patent to lapse.
When Does the Cagrilintide Patent Expire?
US patents last 20 years from their filing date, and Novo Nordisk can request patent term extension to recover time lost to clinical trials and regulatory review. That can add up to five years for one patent in the United States, and Europe offers a comparable supplementary protection certificate.
| Patent type | Typical filing window | Estimated expiry | What it covers |
|---|---|---|---|
| Compound | Early 2010s | Early-to-mid 2030s | The cagrilintide molecule |
| Formulation and composition | Mid 2010s | Mid-to-late 2030s | Injectable liquid formulations |
| Dosing and method of treatment | Late 2010s | Late 2030s | Weekly dosing and titration |
| Combination with semaglutide | Late 2010s to early 2020s | Late 2030s to early 2040s | CagriSema-style co-formulations |
Those dates are estimates rather than legal advice, because real expiry depends on filing dates, claim language, maintenance fees, and whether a patent survives an invalidity challenge. On top of patents, the FDA grants five years of new chemical entity exclusivity and three years of clinical investigation exclusivity to a newly approved drug.
How Cagrilintide Compares With Tirzepatide and Retatrutide
Patent questions usually come up alongside efficacy comparisons, which is why searches for cagrilintide vs tirzepatide and cagrilintide vs retatrutide are so common. Each comparison involves a different company, a different mechanism, and a different exclusivity clock.
| Compound | Developer | Drug class | Status |
|---|---|---|---|
| Cagrilintide | Novo Nordisk | Long-acting amylin analog | Investigational |
| Semaglutide | Novo Nordisk | GLP-1 receptor agonist | Approved |
| Tirzepatide | Eli Lilly | GIP and GLP-1 dual agonist | Approved |
| Retatrutide | Eli Lilly | GIP, GLP-1, and glucagon triple agonist | Investigational |
The practical takeaway is that Novo Nordisk controls cagrilintide while Eli Lilly controls both tirzepatide and retatrutide. That split explains why combination research, patent disputes, and licensing deals in the obesity market tend to run along company lines.
Why the Patent Timeline Matters for Researchers and Buyers
Cagrilintide has not been approved by the FDA for any human use, and the patents covering it remain in force. That combination creates a confusing market for people shopping online.
- US law includes a narrow safe harbor that permits making or using a patented compound solely to generate data for a regulatory submission.
- General "experimental use" defenses are limited in the United States, and a patent holder can pursue unlicensed commercial suppliers.
- Because cagrilintide is investigational, product sold online is not FDA-reviewed for identity, purity, or sterility.
- A generic version cannot legally launch in the US until the relevant patents expire or are invalidated.
Patent status is also a useful reality check when evaluating vendors. A supplier that claims to offer cagrilintide at a generic-level price is selling an unapproved research chemical, not a licensed pharmaceutical.
Safety and Legal Considerations
The most frequently reported cagrilintide side effects in trials have been gastrointestinal — nausea, vomiting, diarrhea, and constipation — along with injection site reactions, and they usually appeared during dose escalation. Anyone researching cagrilintide dosage should know that the numbers circulating online come from trial protocols, not from an approved label.
Self-dosing an investigational peptide carries real risk, so talk with a licensed healthcare professional before considering any unapproved weight-loss drug. Patent protection and safety are separate questions: a drug can be well patented, thoroughly studied, and still not FDA-approved.
The Bottom Line
Novo Nordisk owns the cagrilintide patents, and core compound protection extends into the 2030s with later filings stretching further. No generic cagrilintide can launch in the United States while those patents stand, and the drug itself is not FDA-approved for weight loss or any other indication. Treat unapproved cagrilintide sold online as an unregulated product rather than a legitimate generic.
Frequently Asked Questions
Who owns the cagrilintide patent?
Novo Nordisk owns the cagrilintide patent portfolio. The company developed the long-acting amylin analog and filed the earliest compound patents in the early 2010s, with later formulation, dosing, and combination filings adding further protection.
When does the cagrilintide patent expire?
The core compound patents are expected to expire in the early-to-mid 2030s, assuming a 20-year term plus any patent term extension. Formulation, dosing, and combination patents filed later could keep a cagrilintide product protected into the 2040s. Exact dates depend on individual filings and on whether any patent is successfully challenged.
Is cagrilintide FDA-approved?
No. Cagrilintide has not been approved by the FDA for any indication and remains an investigational drug studied in clinical trials. Any cagrilintide sold online is not FDA-approved, and unapproved peptides are not reviewed for purity, potency, or sterility.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.